scleroderma
SCLERODERMA
Scleroderma is a connective tissue disorder characterized by skin thickening and fibrosis. It is rare, autoimmune and chronic.
It has an idiopathic cause and not contagious.
Early microvascular damage, mononuclear cell infiltrates and slowly developing fibrosis are the important features of the tissue lesions.
The leading causes of death are pulmonary fibrosis and pulmonary arterial hypertension.
  1. MedWormhttp://www.medworm.com/rss/index.php/Dermatology/12/http://www.medworm.com/rss/medicalfeeds/specialities/Dermatology.xml
  2. Denton C. Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults. UpToDate. http://www.uptodate.com/contents/overview-of-the-treatment-and-prognosis-of-systemic-sclerosis-scleroderma-in-adults. Oct 2013. Accessed 29 Oct 2013.
  3. Denton C. Immunomodulatory and antifibrotic approaches to the treatment of systemic sclerosis (scleroderma). UpToDate. http://www.uptodate.com/contents/immunomodulatory-and-antifibrotic-approaches-to-the-treatment-of-systemic-sclerosis-scleroderma. Jul 2013. Accessed 29 Oct 2013.
  4. Denton C. Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults. UpToDate. http://www.uptodate.com/contents/overview-of-the-treatment-and-prognosis-of-systemic-sclerosis-scleroderma-in-adults. Oct 2013. Accessed 05 Mar 2014.
  5. Jacobe H. Treatment of morphea (localized scleroderma) in adults. UpToDate. http://www.uptodate.com/contents/treatment-of-morphea-localized-scleroderma-in-adults. Jun 2013. Accessed 29 Oct 2013.
  6. American College of Rheumatology. Localized scleroderma. American College of Rheumatology. https://www.rheumatology.org/Practice/Clinical/Patients/Diseases_And_Conditions/Localized_Scleroderma_(Juvenile)/. Jun 2012. Accessed 29 Oct 2013.
  7. American College of Rheumatology. Scleroderma (also known as systemic sclerosis). American College of Rheumatology. http://www.rheumatology.org/practice/clinical/patients/diseases_and_conditions/scleroderma.asp. Feb 2013. Accessed 29 Oct 2013.
  8. Arthritis Foundation of Malaysia. Scleroderma. Arthritis Foundation of Malaysia. http://www.afm.org.my/info/scleroderma.htm. Accessed 29 Oct 2013.
  9. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013 Nov;72(11):1747-1755. doi: 10.1136/annrheumdis-2013-204424. Accessed 29 Oct 2013. PMID: 24092682
  10. Varga J. Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults. UpToDate. http://www.uptodate.com/contents/overview-of-the-clinical-manifestations-of-systemic-sclerosis-scleroderma-in-adults. Aug 2013. Accessed 29 Oct 2013.
  11. Varga J. Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults. UpToDate. http://www.uptodate.com/contents/diagnosis-and-differential-diagnosis-of-systemic-sclerosis-scleroderma-in-adults. Nov 2012. Accessed 29 Oct 2013.
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
11 Sep 2019
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.